Cytokine Signalling Forum

Publications





May 17

Romatoid Artritli Hastalarda Tofasitinib'in Düşük Hastalık Aktivitesi Sağlandıktan Sonra Kesilmesi: Çok Merkezli, Gözlemsel Çalışma

Kubo S, Yamaoka K, Amano K, Nagano S, Tohma S, Suematsu E, Nagasawa H, Iwata K and Tanaka Y.
Rheumatology. Doi 10.1093/rheumatology/kex068

This study showed that in patients who achieved low disease activity (LDA), it is possible to discontinue tofacitinib without flare in approximately one-third of patients. Patients from the tofacitinib Phase 3 programme and long-term extension study were enroled. Discontinuation was based on physician-patient decision making with informed consent. The primary endpoint was the proportion of patients who remained tofacitinib free at post-treatment Week 52. Of 64 patients treated with tofacitin...

Keywords: JAK, Tofacitinib

Translated by: Bahtiyar Toz